O Menyhart,B Győrffy
O Menyhart
Background: Immune evasion is a hallmark of cancer and a driver of therapeutic resistance. Although immunotherapy is effective in highly immunogenic cancers, its efficacy in breast cancer (BC) remains limited. We aimed to...
Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives [0.03%]
蛋白工程克服细胞因子在癌症免疫治疗中的限制：目前的策略和未来的展望
U Salazar,P Cioffi,B Taskoparan et al.
U Salazar et al.
Given their central role in immune regulation, cytokines have long been considered attractive therapeutic agents, particularly in cancer immunotherapy. Despite a strong preclinical and clinical rationale, only a limited number of cytokines ...
Comprehensive analysis of the systemic immune landscape across breast cancer subtypes and disease stages [0.03%]
涵盖各类乳腺癌亚型和疾病阶段的系统性免疫全景分析
N A M Bakker,H Garner,V C M Geurts et al.
N A M Bakker et al.
Background: Breast cancer is a systemic disease, yet the impact of tumor molecular subtype and disease stage on the systemic immune landscape remains poorly understood. In this study, we comprehensively analyzed the syste...
Properties of CD8 T-cell-recognized neoantigens in different tumor types [0.03%]
不同肿瘤类型中CD8T细胞识别的新生抗原特性
S L C Ketelaars,M M van Buuren,A Gangaev et al.
S L C Ketelaars et al.
Background: Neoantigen-based immunotherapies rely on computational tools predicting peptide immunogenicity based on properties such as its expression level, binding affinity to human leukocyte antigen (HLA), likelihood of...
Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors [0.03%]
免疫检查点抑制剂治疗黑色素瘤患者的血栓栓塞事件：发病率及风险因素分析
D C H van Dorst,M M Hofman,R M de Waal et al.
D C H van Dorst et al.
Background: Immune checkpoint inhibitors (ICIs) may increase the incidence of thromboembolisms (TEs). In patients with melanoma, the risk of TE and its association with the disease setting remains largely unknown. This st...
A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE) [0.03%]
一项评估纳武利尤单抗、伊匹木单抗和放疗联合流感疫苗治疗胰腺癌患者的II期研究(INFLUENCE)
I M Chen,S Theile,K Madsen et al.
I M Chen et al.
Background: Considering strong T-cell response from influenza vaccination, we aimed to evaluate ipilimumab, nivolumab, seasonal influenza vaccine, and stereotactic body radiotherapy (SBRT) treatment efficacy in heavily pr...
Assessment of CD73 activity in breast cancer-derived small extracellular vesicles: application to monitoring of patients' responses to immunotherapy [0.03%]
乳腺癌来源的小细胞外囊泡的CD73活性评估：在监测患者对免疫疗法反应中的应用
T L Whiteside,S Sehra,T Chadderton et al.
T L Whiteside et al.
Background: We previously discovered that small extracellular vesicles (sEV) isolated from melanoma cells produce immunosuppressive adenosine (ADO) via the ATP→ADP→AMP→ADO pathway and that CD73 is the 'gateway' ecto-nu...
Overcoming antigen loss in CAR T therapy with Vγ9Vδ2 CAR T-cells [0.03%]
具有Vγ9Vδ2CAR-T细胞的CAR-T疗法抗原丢失问题克服策略研究
M Velasco Santiago,P Aehnlich,T M Hulen et al.
M Velasco Santiago et al.
Background: Vγ9Vδ2 T-cells demonstrate potent antitumor activity in vitro but, despite successful safety studies, the clinical benefit of Vγ9Vδ2 in adoptive cell therapy has been limited. One approach to enhance the t...
M Julve,Y N S Wong,K H J Lim et al.
M Julve et al.
Following the Food and Drug Administration (FDA) approval of lifileucel and afami-cel for patients with advanced melanoma and synovial sarcoma, respectively, there is a need for improved understanding and guidance regarding the management o...
An adjusted droplet digital PCR assay for quantification of vector copy number in CAR-T cell and TCR-T cell products [0.03%]
一种用于CAR-T细胞和TCR-T细胞产品中载体拷贝数定量的校正型液滴数字PCR检测方法
J Ma,S Meyer,J Olweus et al.
J Ma et al.
Background: Genetically engineered T-cell therapy holds immense promise in cancer immunotherapy. These T-cell products are typically engineered by vectors that permanently integrate into the T-cell genome, thus raising co...